FdaApplication
BLA 125522
Identifiers
- fda_app_no: BLA125522
Properties
| Property | Value |
|---|---|
| applicant_name | Amgen Inc. |
| application_type | BLA |
| approval_date | 2015-08-27 |
Revenue by product
REPATHA
| Period | Revenue |
|---|---|
| Q2 2026 | $953.0M |
| Q1 2026 | $876.0M |
| Q3 2025 | $794.0M |
| Q2 2025 | $696.0M |
| Q1 2025 | $656.0M |
| Q4 2024 | $606.0M |
| Q3 2024 | $567.0M |
| Q2 2024 | $532.0M |
| Q1 2024 | $517.0M |
| Q4 2023 | $417.0M |
| Q3 2023 | $406.0M |
| Q2 2023 | $424.0M |
| Q1 2023 | $388.0M |
| Q4 2022 | $333.0M |
| Q3 2022 | $309.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
REPATHA
| Period | Revenue |
|---|---|
| Q2 2026 | $953.0M |
| Q1 2026 | $876.0M |
| Q3 2025 | $794.0M |
| Q2 2025 | $696.0M |
| Q1 2025 | $656.0M |
| Q4 2024 | $606.0M |
| Q3 2024 | $567.0M |
| Q2 2024 | $532.0M |
| Q1 2024 | $517.0M |
| Q4 2023 | $417.0M |
| Q3 2023 | $406.0M |
| Q2 2023 | $424.0M |
| Q1 2023 | $388.0M |
| Q4 2022 | $333.0M |
| Q3 2022 | $309.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| REPATHA | EVOLOCUMAB | 140MG/ML | Injection |
| REPATHA | — | 140MG/ML | Injection |
| REPATHA | — | 420MG/3.5ML | Injection |
| REPATHA | — | 140MG/ML | Injection |
4 products